Showing papers by "Herman Mielants published in 1981"
TL;DR: Salsalate caused abnormal gastro-intestinal blood loss in only 2 of the 42 patients studied, which is significantly fewer compared with the soluble, intravenous or enteric-coated forms of acetylsalicylates.
Abstract: In a first stage the effect of a single dose of 3 g of salsalate on serum salicylate level was compared with a single intake of 3 g of soluble or enteric-coated acetylsalicylates in 12 healthy subjects. Salsalate seems to resorb faster than the enteric-coated forms but more slowly than the soluble forms of acetylsalicylate. However, in comparison with these latter forms, salsalate activity is more protracted. In the second part of the study, 42 patients were admitted to a trial in which 3 to 5 g of salsalate was given daily and in which serum salicylate levels and blood loss in stools were measured using the method of labelling red blood cells with Cr. The ideal dosage to obtain a serum salicylate level of 20 mg/100 ml seems to lie between 3 and 4 g of salsalate a day. Salsalate caused abnormal gastro-intestinal Mood loss in only 2 of the 42 patients studied, which is significantly fewer compared with the soluble, intravenous or enteric-coated forms of acetylsalicylates.
23 citations
Journal Article•
TL;DR: It is concluded that levamisole is a useful slow acting antirheumatic drug in rheumatoid patients with benefit in the absence of nephrotoxicity and hepatotoxicity.
Abstract: We evaluated longterm levamisole treatment of 201 rheumatoid patients. Fifty-nine patients in their 1st yr of treatment were not analyzed; of the remaining 142, 69 (49%) still took levamisole with benefit. Levamisole was stopped in 32 patients (22%) for inefficacy and for reversible adverse reactions in 37 (26%). Leukotoxic side-effects were the commonest cause of withdrawal (23 patients = 16%). Since June 1977, we administer levamisole on a 1 d/wk schedule (150 mg), with determination of white blood cells 10 h after intake to detect high-risk patients for agranulocytosis. With disease exacerbation during treatment or lack of response after 6 months, the drug is given on a 2nd non-consecutive day. Since June 1977, cases of agranulocytosis have not been observed. Allergic vasculitis did not occur with a 1 d/wk schedule. The absence of nephrotoxicity and hepatotoxicity is stressed. Only 4 patients (3%) were lost to follow-up. Comparison is made with longterm use of gold and D-penicillamine. We conclude that levamisole is a useful slow acting antirheumatic drug.
20 citations